Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 388, Issue 18, Pages 1657-1667
Publisher
Massachusetts Medical Society
Online
2023-05-04
DOI
10.1056/nejmoa2214963
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
- (2022) Alessio Amatu et al. Cancers
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
- (2022) Andrea Sartore-Bianchi et al. NATURE MEDICINE
- Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
- (2022) Asimina Koulouridi et al. Cancers
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
- (2022) A. Cervantes et al. ANNALS OF ONCOLOGY
- LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
- (2022) N.A. Dasari et al. ANNALS OF ONCOLOGY
- Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
- (2021) Josep Tabernero et al. Future Oncology
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
- (2021) TETSUO ISHIZAKI et al. ANTICANCER RESEARCH
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
- (2021) T. Takahashi et al. ESMO Open
- Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer
- (2021) Erika Martinelli et al. JAMA Oncology
- TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
- (2020) Per Pfeiffer et al. LANCET ONCOLOGY
- Phase Ib/ II Study of Biweekly TAS ‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies ( BiTS Study)
- (2020) Hironaga Satake et al. ONCOLOGIST
- Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
- (2020) Yoichiro Yoshida et al. International Journal of Clinical Oncology
- Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
- (2020) Josep Tabernero et al. ESMO Open
- Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
- (2020) Gianluca Mauri et al. CANCER TREATMENT REVIEWS
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- (2019) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
- (2019) Stig E. Andersen et al. ACTA ONCOLOGICA
- Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
- (2019) Hironori Fujii et al. ONCOLOGIST
- Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
- (2019) Daisuke Kotani et al. BMC CANCER
- Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
- (2018) D Arnold et al. ANNALS OF ONCOLOGY
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- (2018) Chiara Cremolini et al. JAMA Oncology
- TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
- (2017) Yasutoshi Kuboki et al. LANCET ONCOLOGY
- Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
- (2016) Tobias Engel Ayer Botrel et al. BMC CANCER
- Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
- (2016) Mingyi Zhou et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started